Respiratory syncytial virus: Time for surveillance across all ages, with a focus on adults.

"Disclosure of interest: The authors completed the ICMJE Disclosure of Interest Form (available upon request from the corresponding author) and declare the following activities and relationships: LB has regular interaction with pharmaceutical and other industrial partners; he has not received personal fees or other personal benefits. LB is the founding chairman of the ReSViNET Foundation. His institution, the University Medical Centre Utrecht, has received funding for investigator-initiated studies from AbbVie, MedImmune, AstraZeneca, Sanofi, Janssen, Pfizer, MSD, and MeMed Diagnostics; for the RSV GOLD study from the Bill and Melinda Gates Foundation; as part of the public-private partnership IMI-funded RESCEU and PROMISE projects with partners GSK, Novavax, Janssen, AstraZeneca, Pfizer, and Sanofi; by Julius Clinical for participating in clinical studies sponsored by MedImmune and Pfizer; for consultation and invited lectures by AbbVie, MedImmune, Ablynx, Bavarian Nordic, mAbxience, GSK, Novavax, Pfizer, Moderna, AstraZeneca, MSD, Sanofi, Genzyme, and Janssen. MK reports receiving consulting fees from Pfizer and Abbott; payment or honoraria for lectures, presentations, speakers’ bureaus, manuscript writing, or educational events from GSK outside the submitted work. LH is an employee of GSK. HN reports grants from Innovative Medicines Initiative, Pfizer, and Icosavax to his institution; consulting fees from World Health Organization, Pfizer, Bill and Melinda Gates Foundation, and Sanofi to his institution; payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events from AbbVie to his institution; support for attending meetings and/or travel from Sanofi; participation in a Data Safety Monitoring Board or Advisory Board from GSK, Sanofi, Merck, World Health Organization (unpaid), Janssen, Novavax, ReSViNET (unpaid), Icosavax, and Pfizer to his institution, outside the submitted work. TN reports contract funding from GSK to his institution for clinical trials of meningococcal and other vaccines, and personal funding from GSK for scientific advice on various vaccines. He also participated on several Data Safety Monitoring Boards for vaccine trials conducted by other sponsors. HO reports grants from Japan Agency for Medical Research and Development for research in the Philippines including RSV research and from Japan Society for the Promotion of Science for RSV research, outside the submitted work. DS reports consulting fees from GSK, Seqirus, Sanofi, MSD, Pfizer, AstraZeneca, J&J, BioNTech, Moderna, and Clover BioPharmaceuticals."

"Funding: GlaxoSmithKline Biologicals SA funded the advisory board and present work, including all costs associated with the development and publication of this manuscript."